Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 31, Issue 25, 2013, Pages

  Weston, Brent W ^a   Hayden, Melissa A ^b   Roberts, Kathryn G ^c   Bowyer, Susan ^b   Hsu, Johann ^a   Fedoriw, George ^a   Rao, Kathleen W ^a   Mullighan, Charles G ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; CD11B ANTIGEN; CD19 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; HLA DR ANTIGEN; IMATINIB; MERCAPTOPURINE; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; VINCRISTINE; BENZAMIDE DERIVATIVE; EBF1 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; TRANSACTIVATOR PROTEIN; BCR ABL PROTEIN; EARLY B CELL FACTOR 1; FRESH FROZEN PLASMA; JANUS KINASE 1; JANUS KINASE 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHILD; CHROMOSOME ANALYSIS; CONSOLIDATION CHEMOTHERAPY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LEUKEMIA REMISSION; LYMPHADENOPATHY; MALE; MINIMAL RESIDUAL DISEASE; NOTE; PALLOR; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAGITTAL SINUS THROMBOSIS; SCHOOL CHILD; SEIZURE; SINGLE NUCLEOTIDE POLYMORPHISM; SLURRED SPEECH; SPLENOMEGALY; SUPERIOR SAGITTAL SINUS; VISUAL HALLUCINATION; ARTICLE; DRUG ANTAGONISM; GENE REARRANGEMENT; GENETICS; ANTICOAGULATION; BLOOD CLOTTING DISORDER; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; DIMERIZATION; EXON; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HIGH RISK PATIENT; INDUCTION CHEMOTHERAPY; LEUKEMOGENESIS; LEUKOCYTE COUNT; MICROARRAY ANALYSIS; PANCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

BENZAMIDES; CHILD; GENE REARRANGEMENT; HUMANS; MALE; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TRANS-ACTIVATORS;

EID: 84886513092     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.6770     Document Type: Note

References (17)

1. Pui CH, Robison LL, Look AT: Acute lymphoblastic leukaemia. Lancet 371:1030-1043, 2008 (Pubitemid 351389536)
2. Schultz KR, Bowman WP, Aledo A, et al: Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group study. J Clin Oncol 27:5175-5181, 2009
3. Mullighan CG, Su X, Zhang J, et al: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360:470-480, 2009
4. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al: A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study. Lancet Oncol 10:125-134, 2009
5. Roberts KG, Morin RD, Zhang J, et al: Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22:153-166, 2012
6. Loh ML, Harvey RC, Mullighan CG, et al: A BCR-ABL1-like gene expression profile confers a poor prognosis in patients with high-risk acute lymphoblastic leukemia (HR-ALL): A report from Children's Oncology Group (COG) AALL0232. 53rd American Society of Hematology Meeting and Exposition, San Diego, CA, December 10-13, 2011 (abstr 743)
7. Harvey RC, Mullighan CG, Chen IM, et al: Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 115:5312-5321, 2010
8. Mullighan CG, Collins-Underwood JR, Phillips LA, et al: Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 41:1243-1246, 2009
9. Hagman J, Gutch MJ, Lin H, et al: EBF contains a novel zinc coordination motif and multiple dimerization and transcriptional activation domains. EMBO J 14:2907-2916, 1995
10. Cross NC, Reiter A: Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 119:199-206, 2008
11. Carroll M, Tomasson MH, Barker GF, et al: The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinasedependent signaling pathways. Proc Natl Acad Sci U S A 93:14845-14850, 1996
12. Apperley JF, Gardembas M, Melo JV, et al: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481-487, 2002 (Pubitemid 34879335)
13. Cools J, DeAngelo DJ, Gotlib J, et al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201-1214, 2003 (Pubitemid 36359296)
14. David M, Cross NC, Burgstaller S, et al: Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 109:61-64, 2007 (Pubitemid 46053044)
15. Jovanovic JV, Score J, Waghorn K, et al: Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109:4635-4640, 2007 (Pubitemid 46827752)
16. Cornfield D, Shah U, Cross N, et al: Philadelphia chromosome-negative myeloproliferative neoplasm with a novel platelet-derived growth factor receptor- rearrangement responsive to imatinib. J Clin Oncol 30:e109-e111, 2012
17. Kotecha N, Flores NJ, Irish JM, et al: Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 14:335-343, 2008